CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 66 enrolled
Drug / intervention
Lasertherapy +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02066896
NCT02066896N/ACompleted
CompareCT.gov

Low Level Laser Therapy For The Treatment Of Xerostomia In Primary Sjogren's Syndrome

Federal University of São Paulo·interventional·Posted Feb 20, 2014·Updated Aug 3, 2017

In Brief

A clinical study evaluating Lasertherapy and Sham Lasertherapy for KERATOCONJUNCTIVITIS SICCA and 3 related conditions. Completed, enrolled 66 participants across 1 site.

Detailed Summary

This study was designed to test the efficacy and safety of low laser therapy to treat the xerostomia of patients with primary Sjogren's Syndrome.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsKERATOCONJUNCTIVITIS SICCA, XEROSTOMIA, SICCA SYNDROME, PRIMARY SJOGREN SYNDROME
CountriesBrazil
Collaborators--

Timeline

N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedFeb 20, 2014
Enrollment StartMay 1, 2014
Primary CompletionAug 1, 2016
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 12.4 years ago

Interventions

Lasertherapydevice

Laser 808 wave length infrared Ga AlAs(gallium-aluminum-arsenide). The laser beam applied bilaterally in non contact mode to each salivary gland area, extra orally to the parotid and submandibular glands and intramurally to the sublingual gland/ 4 Joules/cm2 each point (active group)

Sham Lasertherapydevice

Laser 808 wave length infrared Ga AlAs(gallium-aluminum-arsenide).The device will be applied with the laser pen closed by aluminium foil (placebo group).